Issue 22

Election 2024: Is Trump or Harris Best for U.S. Biopharma?

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Trump vs. Harris: What Does it Mean for Biopharma?

As the 2024 U.S. election between Donald Trump and Kamala Harris approaches, the biopharma industry is keenly watching how each candidate's policies could shape the future of the sector. 

Read more here.

FEATURED STORIES

Further Opposition Voiced on Novo Holdings’ Catalent Acquisition, While Catalent Sells Facilities

Read more here.

BioDuro-Sundia Opens New Kilo Lab in Shanghai’s FTZ

Read more here.

TuHURA Biosciences Completes Merger with Kintara Therapeutics 

Read more here.

LaNova Medicines Secures $42 Million in Funding to Accelerate Oncology Innovations

Read more here.

Catalent Expands ASD Capabilities in Boston

Read more here.

Sanofi and Orano Partner to Develop Next-Generation Radioligand Cancer Therapies

Read more here.

Evonik Announces 260 More Layoffs as Part of Multi-Year Restructuring

Read more here.

OmniaBio Opens New Facility in Canada to Advance Cell and Gene Therapy Manufacturing 

Read more here.

Celltrion to Establish Wholly-Owned CDMO Subsidiary by End of 2024

Read more here.

AGC Pauses CGT Operations

Read more here.

SpectronRx Announces Collaboration for European Radiotherapy Isotope Manufacturing Facility  

Read more here.

Zealand Pharma Faces Second FDA Rejection Due to CDMO Inspection Issues 

Read more here.

Matica Secures Multiple Viral Vector CDMO Contracts

Read more here.

Afton Scientific to Invest $200 Million on Facility Expansion

Read more here.